The Benefits of Genetic Testing: What Your DNA Can Actually Tell You

Genetic testing has gone from a research curiosity to a mainstream health tool in under a decade. More than 26 million consumers have taken direct-to-consumer DNA tests as of 2024 (Regalado, 2019), and clinical genetic testing volumes have surged alongside them. But beyond the marketing hype, what does the evidence actually say about the benefits of genetic testing for your health?

The answer is more nuanced - and more compelling - than most people realize. From catching hereditary cancers decades early to preventing dangerous drug reactions, genetic testing's real value lies in turning abstract risk into concrete action.

Early Detection of Hereditary Cancer Syndromes

Perhaps the strongest case for genetic testing is hereditary cancer screening. Roughly 5–10% of all cancers are driven by inherited mutations, and identifying carriers before cancer develops can be lifesaving (Garber & Offit, 2005).

The best-studied example is BRCA1 and BRCA2. Women carrying pathogenic BRCA1 variants face a 55–72% lifetime risk of breast cancer and a 39–44% risk of ovarian cancer, compared to 12% and 1.2% in the general population (Kuchenbaecker et al., 2017). For carriers, enhanced screening with breast MRI starting at age 25, and the option of risk-reducing surgery, can reduce cancer mortality by over 90% (Domchek et al., 2010).

Lynch syndrome - caused by mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2) - increases colorectal cancer risk to 40–80% lifetime, along with elevated risks for endometrial, ovarian, gastric, and urinary tract cancers (Bonadona et al., 2011). Early identification allows annual colonoscopies starting at age 20–25, catching precancerous polyps years before they'd otherwise be found.

Other actionable hereditary cancer genes include:

• APC (familial adenomatous polyposis) - near 100% colorectal cancer risk without intervention
• TP53 (Li-Fraumeni syndrome) - lifetime cancer risk exceeding 70%
• PALB2 - breast cancer risk of 33–58% in female carriers (Yang et al., 2020)

The American College of Medical Genetics now recommends that all adults have access to screening for 81 actionable genes, regardless of family history (Miller et al., 2023).

Pharmacogenomics: The Right Drug at the Right Dose

Every year, adverse drug reactions cause an estimated 2.2 million hospitalizations and over 100,000 deaths in the United States alone - making them one of the leading causes of death (Lazarou et al., 1998). Many of these reactions are genetically predictable.

Pharmacogenomics uses your genetic data to determine how you'll metabolize specific drugs. Key examples:

• CYP2D6 variants affect metabolism of over 25% of commonly prescribed drugs, including codeine, tamoxifen, and many antidepressants. Poor metabolizers may get no benefit from codeine (it can't convert to morphine), while ultrarapid metabolizers face overdose risk - a danger particularly acute in children (Crews et al., 2014).
• CYP2C19 determines response to clopidogrel (Plavix), a blood thinner prescribed after heart attacks and stent placement. Poor metabolizers have a 1.5–3.5x increased risk of recurrent cardiovascular events on standard doses (Scott et al., 2013).
• HLA-B*5701 screening before prescribing abacavir (an HIV drug) virtually eliminates a potentially fatal hypersensitivity reaction that occurs in 5–8% of patients (Mallal et al., 2008).

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines for over 20 drug-gene pairs, with evidence strong enough to change prescribing decisions (Relling & Klein, 2011). A large randomized trial (PREPARE) across seven European countries demonstrated that preemptive pharmacogenomic testing reduced adverse drug reactions by 30% compared to standard care (Swen et al., 2023).

Carrier Screening for Family Planning

Carrier screening identifies whether you carry a single copy of a recessive gene mutation. You won't be affected, but if your partner carries the same mutation, each child has a 25% chance of inheriting the condition.

The American College of Obstetricians and Gynecologists recommends offering carrier screening to all individuals considering pregnancy, regardless of ethnicity (ACOG Committee Opinion No. 691, 2017). Expanded panels now screen for over 200 conditions including:

• Cystic fibrosis - 1 in 25 people of European descent are carriers (Watson et al., 2004)
• Spinal muscular atrophy - carrier frequency of 1 in 40–60 across ethnicities
• Sickle cell disease - 1 in 12 African Americans carry the trait
• Tay-Sachs disease - 1 in 30 among Ashkenazi Jewish individuals

Knowing carrier status before conception opens doors: preimplantation genetic testing during IVF, prenatal diagnosis, or simply informed preparation. Studies show that 90% of couples who learn they're both carriers change their reproductive plans in some way (Henneman et al., 2004).

Hereditary Cardiovascular Conditions

Genetic testing is increasingly important for cardiovascular risk. Familial hypercholesterolemia (FH), caused primarily by LDLR, APOB, and PCSK9 mutations, affects 1 in 250 people - making it one of the most common genetic disorders - yet fewer than 10% of cases are diagnosed (Nordestgaard et al., 2013).

Untreated FH carriers have a 20-fold increased risk of premature coronary artery disease. But with early statin therapy, their cardiovascular risk can be reduced to near-normal levels (Versmissen et al., 2008). The catch: without genetic testing, most people with FH don't know they have it until their first heart attack.

Similarly, variants in genes like SCN5A and KCNQ1 cause inherited arrhythmias (Long QT syndrome, Brugada syndrome) that can trigger sudden cardiac death in otherwise healthy young people. Genetic identification allows preemptive treatment with beta-blockers or implantable defibrillators (Schwartz et al., 2012).

Nutrigenomics and Lifestyle Optimization

While the evidence here is earlier-stage than for clinical genetics, several well-studied gene-diet interactions have practical implications:

• MTHFR C677T - the TT genotype (found in 10–15% of European-descent populations) impairs folate metabolism, increasing homocysteine levels and potentially neural tube defect risk. Supplementing with methylfolate instead of folic acid bypasses the deficiency (Crider et al., 2012).
• CYP1A2 and caffeine metabolism - slow metabolizers who drink 4+ cups of coffee daily have a 64% increased risk of nonfatal heart attack (Cornelis et al., 2006). Read our full guide on caffeine metabolism genetics.
• APOE4 - carriers of one ε4 allele have 3x the Alzheimer's risk; two copies increase risk 12-fold (Corder et al., 1993). While no cure exists yet, lifestyle interventions (exercise, Mediterranean diet, cognitive training) show particular benefit in APOE4 carriers (Solomon et al., 2018).
• LCT gene - determines lactose tolerance/intolerance, allowing dietary adjustments based on genetic reality rather than guesswork.
• OCA2/HERC2 and eye color - variants like rs12913832 are the primary determinants of eye color inheritance, illustrating how single SNPs can have large effects on visible traits.

The Limitations - What Genetic Testing Can't Do

Responsible reporting requires acknowledging what genetic testing doesn't tell you:

• Most diseases are polygenic. A single gene variant rarely determines your fate. Environment, lifestyle, and dozens of other genes all contribute.
• Variants of uncertain significance (VUS) are common. Not every detected variant has a known clinical impact.
• Negative results don't mean zero risk. You can still develop breast cancer without a BRCA mutation.
• Psychological impact matters. Some people experience significant anxiety from results. Genetic counseling before and after testing is strongly recommended (Heshka et al., 2008).

What You Can Do With Your Results

If you've already taken a test through 23andMe, AncestryDNA, or another provider, your raw data file contains thousands of health-relevant variants. You can upload your raw DNA data to GenomeInsight for a comprehensive analysis covering over 500 genetic variants across health risks, pharmacogenomics, carrier status, and traits.

Already exploring your genetics? Check out our guides on pharmacogenomics and drug response, MTHFR mutations, or hereditary hemochromatosis.

Want genetics research delivered weekly? Join our newsletter.

Key Takeaways

• Genetic testing can identify hereditary cancer risk decades before symptoms, enabling prevention
• Pharmacogenomic testing reduces adverse drug reactions by ~30% and prevents dangerous drug-gene interactions
• Carrier screening empowers informed family planning for over 200 recessive conditions
• Cardiovascular genetic testing catches conditions like familial hypercholesterolemia that affect 1 in 250 people
• Limitations exist - genetic counseling and understanding polygenic risk are essential
• Your existing raw DNA data already contains actionable health information

---

References

1. Regalado A. More than 26 million people have taken an at-home ancestry test. MIT Technology Review. 2019. https://www.technologyreview.com/2019/02/11/103446/
2. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23(2):276-292. doi:10.1200/JCO.2005.10.042
3. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112
4. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975. doi:10.1001/jama.2010.1237
5. Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304-2310. doi:10.1001/jama.2011.743
6. Yang X, Leslie G, Dorber A, et al. Cancer risks associated with germline PALB2 pathogenic variants. J Clin Oncol. 2020;38(7):674-681. doi:10.1200/JCO.19.01907
7. Miller DT, Lee K, Abul-Husn NS, et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing. Genet Med. 2023;25(8):100866. doi:10.1016/j.gim.2023.100866
8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279(15):1200-1205. doi:10.1001/jama.279.15.1200
9. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376-382. doi:10.1038/clpt.2013.254
10. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317-323. doi:10.1038/clpt.2013.105
11. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579. doi:10.1056/NEJMoa0706135
12. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464-467. doi:10.1038/clpt.2010.279
13. Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions. N Engl J Med. 2023;389(18):1680-1689. doi:10.1056/NEJMoa2303720
14. ACOG Committee Opinion No. 691. Carrier Screening for Genetic Conditions. Obstet Gynecol. 2017;129(3):e41-e55.
15. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med. 2004;6(5):387-391.
16. Henneman L, Borry P, Chokoshvili D, et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet. 2004;24(6):e1-e12.
17. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population. Eur Heart J. 2013;34(45):3478-3490. doi:10.1093/eurheartj/eht273
18. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long-term cohort study. BMJ. 2008;337:a2423. doi:10.1136/bmj.a2423
19. Schwartz PJ, Ackerman MJ, George AL Jr, Wilde AAM. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol. 2013;62(3):169-180. doi:10.1016/j.jacc.2013.04.044
20. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr. 2012;3(1):21-38. doi:10.3945/an.111.000992
21. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006;295(10):1135-1141. doi:10.1001/jama.295.10.1135
22. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923. doi:10.1126/science.8346443
23. Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer's disease and dementia. J Intern Med. 2014;275(3):229-250. doi:10.1111/joim.12178
24. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 2008;10(1):19-32. doi:10.1097/GIM.0b013e31815f524f